This retrospective inception cohort study investigated RA patients starting a new bDMARD or JAKi prescription between 01 August 2018 and 31 January 2022 from IQVIA’s Dutch Real-World Data Longitudinal Prescription database.

December 2022

Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.

Keywords: